Earnings Summary

Reata Pharmaceuticals Inc’s revenue jumped 2885.04% since last year same period to $22.75Mn in the Q2 2023. On a quarterly growth basis, Reata Pharmaceuticals Inc has generated 11564.62% jump in its revenue since last 3-months.

Reata Pharmaceuticals Inc’s net profit jumped 362.39% since last year same period to $193Mn in the Q2 2023. On a quarterly growth basis, Reata Pharmaceuticals Inc has generated 266.21% jump in its net profits since last 3-months.

Reata Pharmaceuticals Inc’s net profit margin jumped 108.79% since last year same period to 848.49% in the Q2 2023. On a quarterly growth basis, Reata Pharmaceuticals Inc has generated 101.42% jump in its net profit margins since last 3-months.

Reata Pharmaceuticals Inc’s earning per share (EPS) estimates for the current quarter stand at -2.21 - a -1.38% fall from last quarter’s estimates.

Reata Pharmaceuticals Inc’s earning per share (EPS) estimates for the current year stand at -2.21.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Reata Pharmaceuticals Inc’s return on assets (ROA) stands at -0.38.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Reata Pharmaceuticals Inc’s return on equity (ROE) stands at -1.12.